Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 9, keine Gesamtzahl für „administer“
Suchtreffer
Begriffe & Kennungen
Briviact (in Italy: Nubriveo) · 4.5 · Strong enzyme inducing AEDs Brivaracetam plasma concentrations are decreased when coadministered with strong e
Eintrag öffnenBriviact (in Italy: Nubriveo) · 4.5 · Table 1: Pharmacokinetic interactions between brivaracetam and other AEDs AED coadministered Influence of AED
Eintrag öffnenBriviact (in Italy: Nubriveo) · 4.5 · Table 1: Pharmacokinetic interactions between brivaracetam and other AEDs AED coadministered Influence of AED
Eintrag öffnenBrukinsa · 4.5 · No clinically significant differences in zanubrutinib pharmacokinetics were observed when co-administered with
Eintrag öffnenBrukinsa · 4.5 · No clinically significant differences in zanubrutinib pharmacokinetics were observed when co-administered with
Eintrag öffnenBuccolam · 4.8 · Published clinical studies show that oromucosal midazolam was administered to approximately 443 children and 2
Eintrag öffnenBuccolam · 4.8 · The table below lists the adverse reactions reported to occur when oromucosal midazolam was administered in cl
Eintrag öffnenBusulfan Fresenius Kabi · 4.5 · Either phenytoin or benzodiazepines were administered for seizure prophylaxis in patients participating to the
Eintrag öffnenBuvidal · 4.5 · 8 expected to have less effects on buprenorphine metabolism when co-administered with Buvidal as compared to w
Eintrag öffnenBuvidal · 4.5 · Buprenorphine should be used cautiously when co-administered with: • naltrexone and nalmefene: These are opioi
Eintrag öffnenBuvidal · 4.5 · Buprenorphine should be used cautiously when co-administered with: • naltrexone and nalmefene: These are opioi
Eintrag öffnenCalquence · 4.5 · ACP-5862 may increase exposure to co-administered MATE1 substrates (e.g., metformin) by inhibition of MATE1 (s
Eintrag öffnenCalquence · 4.5 · ACP-5862 may increase exposure to co-administered MATE1 substrates (e.g., metformin) by inhibition of MATE1 (s
Eintrag öffnenCalquence · 4.5 · Acalabrutinib may increase exposure to co-administered BCRP substrates (e.g., methotrexate) by inhibition of i
Eintrag öffnenCalquence · 4.5 · Acalabrutinib may increase exposure to co-administered BCRP substrates (e.g., methotrexate) by inhibition of i
Eintrag öffnenCapecitabine Accord · 4.5 · Food interaction In all clinical trials, patients were instructed to administer capecitabine within 30 minutes
Eintrag öffnenCapecitabine Medac · 4.5 · Food interaction In all clinical trials, patients were instructed to administer capecitabine within 30 minutes
Eintrag öffnenCapecitabine Teva · 4.5 · 11 capecitabine be administered with food. Administration with food decreases the rate of capecitabine absorpt
Eintrag öffnenCapecitabine Teva · 4.5 · Food interaction In all clinical trials, patients were instructed to administer capecitabine within 30 minutes
Eintrag öffnenCasgevy · 4.8 · The median (min, max) duration of follow-up after being administered Casgevy was 22.8 (2.1, 51.1) months for p
Eintrag öffnen